Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose toripalimab plus irinotecan for third-line advanced gastric cancer
ChiCTR2600133586Phase 4Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toripalimab and irinotecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Shandong Cancer Hospital. Primary endpoint: Median progression-free survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
toripalimabirinotecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600133586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133586.